Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Intercept price target raised to $56 from $51 at Stifel » 12:49
08/10/20
08/10
12:49
08/10/20
12:49
ICPT

Intercept

$49.73 /

+0.98 (+2.01%)

Stifel analyst Derek…

Stifel analyst Derek Archila raised the firm's price target on Intercept to $56 from $51 after the company reported Q2 Ocaliva sales that were ahead of consensus forecasts. However, he keeps a Hold rating on the shares as there "remains a big question mark in terms of resolving the complete response letter" the company received in June. While Intercept management said they expect to have an FDA Type A meeting by early Q4, they noted that a single meeting may not be enough to reach alignment with respect to an NDA refiling, Archila tells investors.

ShowHide Related Items >><<
ICPT Intercept
$49.73 /

+0.98 (+2.01%)

ICPT Intercept
$49.73 /

+0.98 (+2.01%)

08/10/20 Piper Sandler
Piper Sandler confident in success of Intercept's OCA approval in 2021
07/30/20 Piper Sandler
Intercept initiated with an Overweight at Piper Sandler
07/21/20 JMP Securities
Intercept downgraded to Market Perform from Outperform at JMP Securities
06/30/20 Citi
Citi upgrades Intercept following pullback ahead of likely NDA refiling
ICPT Intercept
$49.73 /

+0.98 (+2.01%)

ICPT Intercept
$49.73 /

+0.98 (+2.01%)

Recommendations
Piper Sandler confident in success of Intercept's OCA approval in 2021 » 11:54
08/10/20
08/10
11:54
08/10/20
11:54
ICPT

Intercept

$49.49 /

+0.74 (+1.52%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi is confident in the success of Intercept's NDA submission and approval of OCA in 2021, especially with numerous upcoming datasets at the virtual EASL conference that provide more fuel to win the "risk-benefit" argument raised by the FDA. Rahimi, who made no change to the firm's Overweight rating or $82 price target, thinks Intercept is well-funded ahead of addressing the CRL and possible OCA approval for NASH in 2021.

ShowHide Related Items >><<
ICPT Intercept
$49.49 /

+0.74 (+1.52%)

ICPT Intercept
$49.49 /

+0.74 (+1.52%)

07/30/20 Piper Sandler
Intercept initiated with an Overweight at Piper Sandler
07/21/20 JMP Securities
Intercept downgraded to Market Perform from Outperform at JMP Securities
06/30/20 Citi
Citi upgrades Intercept following pullback ahead of likely NDA refiling
06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
ICPT Intercept
$49.49 /

+0.74 (+1.52%)

ICPT Intercept
$49.49 /

+0.74 (+1.52%)

Earnings
Intercept sees 2020 Ocaliva sales $300M-$320M » 07:06
08/10/20
08/10
07:06
08/10/20
07:06
ICPT

Intercept

$48.75 /

+1.63 (+3.46%)

Revenue consensus…

Revenue consensus $288.07M. Sees 220 adjusted operating expenses $460M-$500M.

ShowHide Related Items >><<
ICPT Intercept
$48.75 /

+1.63 (+3.46%)

ICPT Intercept
$48.75 /

+1.63 (+3.46%)

07/30/20 Piper Sandler
Intercept initiated with an Overweight at Piper Sandler
07/21/20 JMP Securities
Intercept downgraded to Market Perform from Outperform at JMP Securities
06/30/20 Citi
Citi upgrades Intercept following pullback ahead of likely NDA refiling
06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
ICPT Intercept
$48.75 /

+1.63 (+3.46%)

ICPT Intercept
$48.75 /

+1.63 (+3.46%)

Hot Stocks
Intercept no longer expects to launch OCA for NASH in 2020 » 07:04
08/10/20
08/10
07:04
08/10/20
07:04
ICPT

Intercept

$48.75 /

+1.63 (+3.46%)

The company said,…

The company said, "On June 29, 2020, we announced that the U.S. Food and Drug Administration had issued a Complete Response Letter egarding our New Drug Application for OCA for the treatment fibrosis due to NASH. As a result, we no longer expect to launch OCA for NASH in 2020."

ShowHide Related Items >><<
ICPT Intercept
$48.75 /

+1.63 (+3.46%)

ICPT Intercept
$48.75 /

+1.63 (+3.46%)

07/30/20 Piper Sandler
Intercept initiated with an Overweight at Piper Sandler
07/21/20 JMP Securities
Intercept downgraded to Market Perform from Outperform at JMP Securities
06/30/20 Citi
Citi upgrades Intercept following pullback ahead of likely NDA refiling
06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
ICPT Intercept
$48.75 /

+1.63 (+3.46%)

ICPT Intercept
$48.75 /

+1.63 (+3.46%)

Earnings
Intercept reports Q2 EPS ($1.92), consensus ($2.92) » 07:03
08/10/20
08/10
07:03
08/10/20
07:03
ICPT

Intercept

$48.75 /

+1.63 (+3.46%)

Reports Q revenue $77.2M,…

Reports Q revenue $77.2M, consensus $72.15M. "Our PBC business achieved its highest quarterly net sales to date in the second quarter," said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept. "We plan to continue to invest in our growing PBC business and announced 2020 Ocaliva net sales guidance earlier this morning. We anticipate that our Ocaliva net sales, together with the announced reduction in our 2020 non-GAAP adjusted operating expense guidance, will help to ensure that we are financially well positioned to support the path forward in NASH. In the meantime, we are preparing to meet with the FDA to discuss the basis for resubmission of our NDA seeking accelerated approval of OCA for the treatment of advanced fibrosis due to NASH, and continue to believe that OCA has the potential to become the foundational treatment for these patients. I am encouraged by the outpouring of support we have received from the liver community in recent weeks and we remain committed to our goal of bringing the first therapy to market for patients with this serious condition."

ShowHide Related Items >><<
ICPT Intercept
$48.75 /

+1.63 (+3.46%)

ICPT Intercept
$48.75 /

+1.63 (+3.46%)

07/30/20 Piper Sandler
Intercept initiated with an Overweight at Piper Sandler
07/21/20 JMP Securities
Intercept downgraded to Market Perform from Outperform at JMP Securities
06/30/20 Citi
Citi upgrades Intercept following pullback ahead of likely NDA refiling
06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
ICPT Intercept
$48.75 /

+1.63 (+3.46%)

ICPT Intercept
$48.75 /

+1.63 (+3.46%)

Over a week ago
Initiation
Intercept initiated with an Overweight at Piper Sandler » 16:05
07/30/20
07/30
16:05
07/30/20
16:05
ICPT

Intercept

$46.64 /

+1.04 (+2.28%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Intercept Pharmaceuticals with an Overweight rating and $82 price target. The analyst has "significant conviction" that Intercept will provide regulators with "compelling" histological and non-invasive datasets that can resolve the FDA's main question over the outcomes benefit-risk ratio for Ocaliva treatment. Further, readout of outcomes benefit for OCA in cirrhotics and label expansion would be a significant value driver in the medium term, says the analyst.

ShowHide Related Items >><<
ICPT Intercept
$46.64 /

+1.04 (+2.28%)

ICPT Intercept
$46.64 /

+1.04 (+2.28%)

07/21/20 JMP Securities
Intercept downgraded to Market Perform from Outperform at JMP Securities
06/30/20 Citi
Citi upgrades Intercept following pullback ahead of likely NDA refiling
06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
06/30/20 SVB Leerink
Intercept price target lowered to $50 from $89 at SVB Leerink
ICPT Intercept
$46.64 /

+1.04 (+2.28%)

ICPT Intercept
$46.64 /

+1.04 (+2.28%)

Downgrade
Intercept downgraded to Market Perform from Outperform at JMP Securities » 06:06
07/21/20
07/21
06:06
07/21/20
06:06
ICPT

Intercept

$48.08 /

-0.78 (-1.60%)

JMP Securities analyst…

JMP Securities analyst Jonathan Wolleben assumed coverage of Intercept with a Market Perform rating, down from the firm's previous Outperform rating, without a price target. Wolleben says the complete response letter regarding the NDA for obeticholic acid to treat fibrosis due to NASH "caught us by surprise," but notes that the review cycle "already had its twists and turns." Wolleben says the reorganization of the FDA's Office of New Drugs and the COVID-19 pandemic likely didn't make the review process any easier. Given the lack of visibility for OCA in NASH, the analyst is stepping to the sidelines.

ShowHide Related Items >><<
ICPT Intercept
$48.08 /

-0.78 (-1.60%)

ICPT Intercept
$48.08 /

-0.78 (-1.60%)

06/30/20 Citi
Citi upgrades Intercept following pullback ahead of likely NDA refiling
06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
06/30/20 SVB Leerink
Intercept price target lowered to $50 from $89 at SVB Leerink
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
ICPT Intercept
$48.08 /

-0.78 (-1.60%)

ICPT Intercept
$48.08 /

-0.78 (-1.60%)

Over a month ago
Upgrade
Citi upgrades Intercept following pullback ahead of likely NDA refiling » 09:56
06/30/20
06/30
09:56
06/30/20
09:56
ICPT

Intercept

$45.81 /

-0.83 (-1.78%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty upgraded Intercept to Buy from Neutral with a price target of $67, down from $110, as he believes the stock now offers a favorable risk/reward following the pullback in response to the complete response letter issued by the FDA. While he now gives Intercept a 50% probability of approval for obeticholic acid in nonalcoholic steatohepatitis, down from 90% previously, Beatty believes it is likely that the company will be able to refile an NDA in the next several months based on data that already exists and get an advisory committee meeting convened. He also believes there is a strong consensus in the hepatology community that supports approval of OCA for NASH and that an AdCom vote would likely be favorable, Beatty tells investors.

ShowHide Related Items >><<
ICPT Intercept
$45.81 /

-0.83 (-1.78%)

ICPT Intercept
$45.81 /

-0.83 (-1.78%)

06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
06/30/20 SVB Leerink
Intercept price target lowered to $50 from $89 at SVB Leerink
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/30/20 Baird
Intercept downgraded to Neutral following "surprise" FDA decision at Baird
ICPT Intercept
$45.81 /

-0.83 (-1.78%)

ICPT Intercept
$45.81 /

-0.83 (-1.78%)

On The Fly
Moderna, PayPal coverage initiations among today's top calls on Wall Street » 09:55
06/30/20
06/30
09:55
06/30/20
09:55
MRNA

Moderna

$63.09 /

+0.99 (+1.59%)

, PYPL

PayPal

$170.20 /

+1.89 (+1.12%)

, SQ

Square

$104.05 /

+0.34 (+0.33%)

, SPOT

Spotify

$263.74 /

-1.59 (-0.60%)

, WMG

Warner Music

$31.50 /

+0.035 (+0.11%)

, TME

Tencent Music

$13.83 /

+0.575 (+4.34%)

, ICPT

Intercept

$45.67 /

-0.97 (-2.08%)

, CLX

Clorox

$220.49 /

+3.01 (+1.38%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
WMG Warner Music
$31.50 /

+0.035 (+0.11%)

TME Tencent Music
$13.83 /

+0.575 (+4.34%)

SQ Square
$104.05 /

+0.34 (+0.33%)

SPOT Spotify
$263.74 /

-1.59 (-0.60%)

PYPL PayPal
$170.20 /

+1.89 (+1.12%)

MRNA Moderna
$63.09 /

+0.99 (+1.59%)

ICPT Intercept
$45.67 /

-0.97 (-2.08%)

CLX Clorox
$220.49 /

+3.01 (+1.38%)

MRNA Moderna
$63.09 /

+0.99 (+1.59%)

06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
PYPL PayPal
$170.20 /

+1.89 (+1.12%)

06/30/20 Canaccord
PayPal price target raised to $190 from $160 at Canaccord
06/30/20 Citi
PayPal remains a top idea at Citi
06/30/20 JMP Securities
PayPal initiated with an Outperform at JMP Securities
06/24/20
Fly Intel: Top five analyst downgrades
SQ Square
$104.05 /

+0.34 (+0.33%)

06/30/20 JMP Securities
Square initiated with a Market Perform at JMP Securities
06/29/20 KeyBanc
Square price target raised to $125 from $70 at KeyBanc
06/23/20 Rosenblatt
Rosenblatt sees crypto offering fitting well with PayPal user base
06/22/20 Barclays
Square price target raised to $115 from $90 at Barclays
SPOT Spotify
$263.74 /

-1.59 (-0.60%)

06/30/20 Citi
Spotify initiated with a Neutral at Citi
06/29/20
Fly Intel: Top five analyst downgrades
06/29/20 Guggenheim
Guggenheim cuts Spotify to Sell with potential podcast dominance priced in
06/29/20 Morgan Stanley
Spotify price target raised to $275 from $190 at Morgan Stanley
WMG Warner Music
$31.50 /

+0.035 (+0.11%)

06/30/20 Loop Capital
Warner Music initiated with a Hold at Loop Capital
06/30/20 Citi
Warner Music initiated with a Neutral, $33 target at Citi
06/30/20 Citi
Warner Music initiated with a Neutral at Citi
06/29/20 Loop Capital
Warner Music initiated with a Hold at Loop Capital
TME Tencent Music
$13.83 /

+0.575 (+4.34%)

06/30/20 UBS
Tencent Music upgraded to Buy from Neutral at UBS
06/30/20 Citi
Tencent Music initiated with a Buy at Citi
03/18/20 Bocom
Tencent Music upgraded to Neutral from Sell at BOCOM
03/12/20 Morgan Stanley
Tencent Music upgraded to Overweight from Equal Weight at Morgan Stanley
ICPT Intercept
$45.67 /

-0.97 (-2.08%)

06/30/20 Citi
Intercept upgraded to Buy from Neutral at Citi
06/30/20 SVB Leerink
Intercept price target lowered to $50 from $89 at SVB Leerink
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/30/20 Baird
Intercept downgraded to Neutral following "surprise" FDA decision at Baird
CLX Clorox
$220.49 /

+3.01 (+1.38%)

06/30/20 DA Davidson
Clorox initiated with a Buy at DA Davidson
06/29/20 DA Davidson
Clorox initiated with a Buy at DA Davidson
06/03/20 Credit Suisse
Clorox price target raised to $185 from $180 at Credit Suisse
05/04/20 Credit Suisse
Clorox price target raised to $180 from $172 at Credit Suisse
TME Tencent Music
$13.83 /

+0.575 (+4.34%)

SQ Square
$104.05 /

+0.34 (+0.33%)

SPOT Spotify
$263.74 /

-1.59 (-0.60%)

PYPL PayPal
$170.20 /

+1.89 (+1.12%)

MRNA Moderna
$63.09 /

+0.99 (+1.59%)

ICPT Intercept
$45.67 /

-0.97 (-2.08%)

CLX Clorox
$220.49 /

+3.01 (+1.38%)

  • 03
    Jun
  • 19
    May
  • 12
    Feb
WMG Warner Music
$31.50 /

+0.035 (+0.11%)

TME Tencent Music
$13.83 /

+0.575 (+4.34%)

SQ Square
$104.05 /

+0.34 (+0.33%)

SPOT Spotify
$263.74 /

-1.59 (-0.60%)

PYPL PayPal
$170.20 /

+1.89 (+1.12%)

MRNA Moderna
$63.09 /

+0.99 (+1.59%)

CLX Clorox
$220.49 /

+3.01 (+1.38%)

WMG Warner Music
$31.50 /

+0.035 (+0.11%)

TME Tencent Music
$13.83 /

+0.575 (+4.34%)

SQ Square
$104.05 /

+0.34 (+0.33%)

SPOT Spotify
$263.74 /

-1.59 (-0.60%)

PYPL PayPal
$170.20 /

+1.89 (+1.12%)

MRNA Moderna
$63.09 /

+0.99 (+1.59%)

ICPT Intercept
$45.67 /

-0.97 (-2.08%)

CLX Clorox
$220.49 /

+3.01 (+1.38%)

WMG Warner Music
$31.50 /

+0.035 (+0.11%)

TME Tencent Music
$13.83 /

+0.575 (+4.34%)

SQ Square
$104.05 /

+0.34 (+0.33%)

SPOT Spotify
$263.74 /

-1.59 (-0.60%)

PYPL PayPal
$170.20 /

+1.89 (+1.12%)

MRNA Moderna
$63.09 /

+0.99 (+1.59%)

CLX Clorox
$220.49 /

+3.01 (+1.38%)

Upgrade
Intercept upgraded to Buy from Neutral at Citi » 09:50
06/30/20
06/30
09:50
06/30/20
09:50
ICPT

Intercept

$46.13 /

-0.51 (-1.09%)

Citi analyst Joel Beatty…

Citi analyst Joel Beatty upgraded Intercept to Buy from Neutral.

ShowHide Related Items >><<
ICPT Intercept
$46.13 /

-0.51 (-1.09%)

ICPT Intercept
$46.13 /

-0.51 (-1.09%)

06/30/20 SVB Leerink
Intercept price target lowered to $50 from $89 at SVB Leerink
06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/30/20 Baird
Intercept downgraded to Neutral following "surprise" FDA decision at Baird
06/30/20 BMO Capital
Intercept downgraded to Market Perform from Outperform at BMO Capital
ICPT Intercept
$46.13 /

-0.51 (-1.09%)

ICPT Intercept
$46.13 /

-0.51 (-1.09%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.